Now Available!
Partner News | Published: Tuesday, October 15, 2024
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is excited to announce a new partnership with Shockwave Medical, a pioneer in the introduction of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease.
Shockwave IVL is an enhanced application of lithotripsy, an approach that uses sonic pressure waves to safely break up kidney stones. It is widely used to treat problematic calcium in the coronary and peripheral vasculature. Its unique mechanism of action utilizes acoustic sonic pressure waves, also known as shockwaves, that modify calcium prior to definitive therapy to optimize acute and long-term outcomes. Combined with its familiar angioplasty balloon-based platform, Shockwave IVL modifies superficial and deep calcium while being predictably safe, distinctively intuitive and consistently effective.
“MedAxiom is thrilled to welcome Shockwave Medical to the community. We strive to connect MedAxiom members with innovators in industry who offer safe and reliable solutions to challenges, and Shockwave Medical is a great example of this with their IVL technology,” said Joe Sasson, PhD, MedAxiom’s EVP of Ventures and chief commercial officer. “We have been following the Shockwave journey from inception, and this game-changing technology brings an important dimension to cardiovascular care for patients with calcified coronary and peripheral arterial disease. MedAxiom is looking forward to supporting Shockwave in its efforts to improve cardiovascular outcomes for patients.
About MedAxiom
MedAxiom, an ACC Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.
About Shockwave Medical, Inc.
Shockwave Medical, part of Johnson & Johnson MedTech, is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Its Reducer technology, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom, is designed to provide relief to the millions of patients worldwide suffering from refractory angina by redistributing blood flow within the heart. Learn more at http://www.shockwavemedical.com.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.